Bristol Myers Squibb Chief Medical Officer Cristian Massacesi, M.D., has told Fierce that the latest data for its ...

Roche has shed more light on its investigational KRAS G12C inhibitor's phase 3 victory over Amgen’s Lumakras and Bristol Myers Squibb’s Krazati. | Roche has shed more light on its investigational KRAS ...

AstraZeneca executives were adamant that detailed data from a phase 3 study of the pharma’s next-generation antibody-drug ...

The Big Pharma has already launched a phase 2 trial of JNJ-6143 at a 50 mg daily dose in around 100 patients with metastatic androgen pathway modulation-resistant prostate cancer (mAPMR), an advanced ...

Merck & Co. and Moderna always knew they would be making headlines in Madrid this week—just not in the way it panned out. | Merck & Co. and Moderna always knew they would be making headlines in Madrid ...

Eli Lilly has shared phase 1 data on an antibody-drug conjugate (ADC) in platinum-sensitive ovarian cancer (PSOC), shedding light on the company’s chances of competing for a market targeted by rivals ...

Gilead has struck a deal to acquire PepStar Therapeutics’ oral IL-23 receptor inhibitor program for $1.275 billion, positioning itself as a would-be challenger to Johnson & Johnson’s Icotyde across a ...

Bolt Biotherapeutics is acquiring Prana Therapies in a stock-for-stock reverse merger aimed at advancing Prana’s pipeline of antibodies targeting inflammatory conditions. | Bolt Biotherapeutics is ...

Takeda has lifted the lid on the phase 3 win for its next-generation claudin18.2 drug, with the antibody-drug conjugate (ADC) demonstrating overall survival (OS) of 10.2 months in tough to treat ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

| Pathos AI has closed a $237 million series E round led by pharma giant Bristol Myers Squibb on the same day that the two companies signed a cutting-edge Alzheimer's disease-focused collaboration.

Despite the sweeping scope of the ban covering various types of drug molecules, biopharma business development teams can ...